Syndax Says Revumenib NDA Granted FDA Priority Review
By Stephen Nakrosis
Syndax Pharmaceuticals on Tuesday said the U.S. Food and Drug Administration granted a priority review to the new drug application for revumenib as a treatment for certain leukemia patients.
The NDA filing is being reviewed under the FDA's real-time oncology review program, Syndax said. The company added the review has been given a Prescription Drug User Fee Act target action date of Sept. 26.
Syndax said the review is being supported by positive data from the AUGMENT-101 trial of revumenib in adult and pediatric patients with KMT2Ar acute myeloid leukemia and acute lymphoid leukemia. The company previously reported that the trial met its primary endpoint.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 26, 2024 16:48 ET (20:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise